CStone announces registrational study of sugemalimab for first-line treatment of locally advanced or metastatic gastric adenocarcinoma, gastroesophageal junction adenocarcinoma met primary endpoint

China - CStone Pharmaceuticals ('CStone', HKEX: 2616), a leading biopharmaceutical company focused on research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, today announced that the GEMSTONE-303 study, in which sugemalimab in combination with chemotherapy is used as a first-line treatment of unresectable locally advanced or metastatic gastric adenocarcinoma/gastro-esophageal junction adenocarcinoma with PD-L1 expression 5%, has met one of its primary endpoints, progression-free survival (PFS).

Sugemalimab in combination with chemotherapy demonstrated statistically significant and clinically meaningful improvement in investigator-assessed PFS, compared with placebo plus chemotherapy, HR=0.66 (95% CI: 0.54, 0.81), p-value

(C) 2022 Electronic News Publishing, source ENP Newswire